Tryp Therapeutics Submits IND Application for Phase 2a Clinical Trial in FibromyalgiaIrwin Naturals Bringing Its Household Name Brand to the Psychedelic Mental Health SpaceTryp Therapeutics Announces Inclusion in AdvisorShares Psychedelics ETFMindMed and Liechti Lab Provide Results from their Psilocybin R&D CollaborationPsyched Wellness Announces Inclusion in AdvisorShares Psychedelics Exchange Traded Fund (ETF)Tryp Therapeutics Submits IND Application for Phase 2a Clinical Trial in Eating DisordersPsyched Wellness Initiates a Clinical Sleep Study on Humans for a Structure/Function Claim For AME-1Mindset Pharma Selects Treatment-Resistant Depression and End of Life Cancer Angst as Indications for MSP-1014, its NoveHow Will The Data Protection Ruling On Ketamine Impact Psychedelic Novel Drug Development Moving Forward?Mindset Pharma Announces its Next Generation Novel 5-MeO-DMT Psychedelic AnalogsSilo Pharma Advances Psychedelic Patent PortfolioTryp Therapeutics Completes Psychotherapy Training for Phase 2a Study at the University of FloridaMajor Psychedelic Clinical Trial Data Is Right Around The CornerPsychedelic Drug Development Companies Are Leveraging Bolt On MedTech Acquisitions To Create A More Robust Patient Care 7 Psychedelic Clinical Trials Underway That Investors Should Keep On Their RadarNuminus Wellness Closes Q3 2021 With $63.2 Million Cash Position, Lab and Trial Advances, and Strategic Expansion into PSilo Pharma Awarded Notice of Allowance from United States Patent and Trademark Office for Homing Peptide PatentTryp Therapeutics Announces Q3 2021 Financial ResultsKetamine One’s IRP Clinic Using Innovative NeuroCatch Platform to Measure Brain Function in Injured VeteransWake Network, Inc. and the Lieber Institute for Brain Development Announce Research Collaboration

Numinus Wellness Has Big Plans To Scale Operations In The Back Half of 2020 Following A Major License Amendment By Health Canada

Jun 16, 2020 • 7:57 AM EDT
5 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

Although 2020 has been a challenging year for the global economy, we believe that there are a number of pockets of opportunity that our readers need to be aware of. The psychedelic therapy market has been an emerging opportunity and is an industry that has been generating significant traction.

Numinus Wellness Inc. (NUMI.V) represents a multi-faceted growth opportunity that is levered to the psychedelic therapy market. The company recently commenced trading on the TSX Venture Exchange and represents a differentiated growth opportunity.

Through its wholly owned subsidiary Salvation Botanicals, Numinus has a 7,000 square foot laboratory that is licensed by Health Canada to import, export, test, research and produce psychedelic substances. The lab is also approved to test and analyze cannabis products and we are favorable on the structure of the operation.

In the back half of 2020, we expect to see Numinus announce a number of milestones and believe that the opportunity has a favorable risk-reward profile. Last month, the company issued an update on its plans to scale operations and we are bullish on the amount of value that can be generated through this strategy. Some of Numinus’ plans for 2020 include:

  • Upgrading the existing laboratory and processing facilities and obtaining a GMP certification to facilitate R&D and clinical studies
  • The company plans to execute on inorganic growth initiatives via the acquisition of wellness facilities in North America
  • Through strategic partnerships, the company plans to advance the psychedelic therapy protocol development
  • The team is working to identify and construct a purpose-built facility to complement the existing wellness center. Psychedelic assisted therapies will only be available at the purpose-built facility through research or clinical trials (once approved)
  • The company plans to list on the US and European securities exchanges to provide investment opportunities for international markets

Receives Major Licensed Amendment From Health Canada

Last week, Numinus reported a major milestone and was granted approval from Health Canada to amend an existing license under the Controlled Drug and Substances Act to allow it to conduct research to standardize the extraction of psilocybin from mushrooms. The reason why the amendment is a milestone is because it makes Numinus the first publicly traded company in Canada to be granted a license by Health Canada to conduct research of this kind.

Going forward, Numinus is able to produce naturally sourced, sustainable psilocybin for research purposes that will support the psychedelic assisted therapy and research market. The license also allows the company to develop and license its own exclusive IP for further product development in partnership with leading research organizations. The license puts Numinus in a league of its own and we find this to be of importance.

Numinus senior research scientists Dr. Kristina Grotzinger and Dr. Bernd Keller will focus on developing a proprietary extraction method from mushrooms to allow for consistent dosing and application of naturally produced psilocybin. Once a proprietary method has been developed, the company intends to explore supply agreements with leading research organizations to make use of the product in their clinical and therapeutic work.

We believe that the license amendment represents an important development for the business, and this is an attractive aspect of the story. We are favorable on the human capital that is involved with the operation and believe that our readers need to be aware of this facet of the company.

A Multi-Faceted Psychedelics Leader

Numinus is comprised of a number of divisions and we are favorable on the amount of value that can be found between these assets. Through Numinus Wellness, the business is dedicated to providing access for therapies that enhance and supplement existing options for people who want to improve physical, mental and emotional health with psychedelic treatments. Through Numinus R&D, the company is creating partnerships with leading research organizations to advance the industry.

When compared to other companies that are focused on the psychedelic therapy market, Numinus represents a differentiated opportunity that has visible growth prospects. We believe that the structure of the business provides it with the opportunity to recognize significant synergies between its divisions and find this to be an attractive aspect of the story.

The company’s platform includes a testing and research facility that can leverage the development of psychedelic therapies to supplement existing options in addressing mental illness, addictions, and post-traumatic-stress disorder (PTSD). Numinus also has an established and fully integrated therapy and wellness center model that it plans to scale globally.

Numinus is led by a management team that has a proven track record of success in a variety of high growth verticals. When it comes to any early stage company, the management team is often the most important aspect of the story and we are favorable on the people that are in place at Numinus. We believe that the management team is focused on bringing the business down a path to profitability while creating value for shareholders.

If you are interested in learning more about Numinus, please send an email to to be added to our distribution list.









Pursuant to an agreement between StoneBridge Partners LLC and Numinus Wellness Inc.. (NUMI) we have been hired for a period of 180 days beginning April 15, 2020 and ending October 15, 2020 to publicly disseminate information about (NUMI) including on the Website and other media including Facebook and Twitter. We are being paid $7,500 per month (NUMI) for or were paid “0” shares of restricted common shares. We own zero shares of (NUMI), which we purchased in the open market. We plan to sell the “ZERO” shares of (NUMI) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of (NUMI) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

Share Share - Facebook Share - Twitter


Authored By

Michael Berger


Top Stories

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.